Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers

Critical Reviews in Oncology/Hematology

Volumn 46, Issue SUPPL., 2003, Pages 105-115

  Sternberg, Cora N ^a   Vogelzang, Nicholas J ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Anti angiogenesis; Chemotherapy; Kidney cancer; Mini allo stem cell transplantation; Renal cancer; Targeted therapy; Urothelial cancer; VEGF

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; AVITRIPTAN; CARBOPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EDOTECARIN; EPOTHILONE DERIVATIVE; GEMCITABINE; IXABEPILONE; LONAFARNIB; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; TIPIFARNIB; VINFLUNINE;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CELL CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DIARRHEA; FOLATE METABOLISM; HUMAN; KIDNEY CARCINOMA; LUNG TOXICITY; NEUTROPENIA; SIDE EFFECT; UROGENITAL TRACT TUMOR;

EID: 0037678524     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00068-4     Document Type: Conference Paper

References (93)

1. Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Geller N., Herr H.W., Morse M.J., Sogani P.C., Darracott Vaughan E., Bander N., Weiselberg L., Rosado K., Smart T., Lin S.-Y., Penenberg D., Fair W.R., Whitmore W.F. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer. 64:1989;2448-2458.
2. Loehrer P., Einhorn L.H., Elson P.J., Crawford E.D., Kuebler P., Tannock I., Raghavan D., Stuart-Harris R., Sarosdy M.F., Lowe B.A., Blumenstein B., Trump D. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10:1992;1066-1073.
3. Bellmunt J., Albanell J., Gallego O.S., Ribas A., Vicente P., Carulla J., DeTorres J., Morote J., Lopez M., Sole A. Carboplatin, methotrexate and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer. 70:1992;1974-1979.
4. Sternberg C.N. Gemcitabine in bladder cancer. Semin. Oncol. 27:(1, Suppl. 2):2000;31-39.
5. Vogelzang N.J. Future directions for gemcitabine in the treatment of genitourinary cancer. Semin. Oncol. 29:(1, Suppl. 3):2002;40-45.
6. Roth B.J., Dreicer R., Einhorn L.H. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 12:(11):1994;2264-2270.
7. de Wit R., Kruit W.H., Stoter G., de Boer M., Kerger J., Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer: results of a phase II study in non-chemotherapy pretreated patients. Br. J. Cancer. 78:(10):1998;1342-1345.
8. Hussain M., Vaishampayan U., Smith D.C. Novel gemcitabine-containing triplets in the management of urothelial cancer. Semin. Oncol. 29:(1, Suppl. 3):2002;20-24.
9. Bellmunt J., Albanell J., Paz-Ares L., Climent M.A., Gonzalez-Larriba J.L., Carles J., de la Cruz J.J., Guillem V., Diaz-Rubio E., Cortés-Funes H., Baselga J. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin and gemcitabine. Cancer. 95:(4):2002;751-757.
10. Sternberg CN, de Mulder PHM, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C, Collette L, for the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose intensity M-VAC chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic M-VAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer. Protocol No. 30924, J. Clin. Oncol. 2001;19(10):2638-46.
11. von der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., Bodrogi I., Albers P., Knuth A., Lippert M.C., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S.P., Roychowdhury D.F., Tomlin I., Visseren-Grul C.M., Conte P.F. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multi-center phase III study. J. Clin. Oncol. 18:(17):2000;3068-3077.
12. Sternberg C.N., Calabrò F. The management of bladder cancer in the elderly. Tumori. 88:(1, Suppl. 1):2002;S128-S129.
13. Bellmunt J., de Wit R., Albanell J., Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer. Eur. J. Cancer. 37:(17):2001;2212-2215.
14. Stadler W.M. Gemcitabine doublets in advanced urothelial cancer. Semin. Oncol. 29:(1, Suppl. 3):2002;15-19.
15. Small E.J., Lew D., Redman B.G., Petrylak D.P., Hammond N., Gross H.M., Eastham J.A., Crawford E.D. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional cell carcinoma: the importance of survival as a clinical trial end point. J. Clin. Oncol. 18:(13):2000;2537-2544.
16. Vaughn D.J., Malkowicz S.B., Zoltick B., Mick R., Ramchandani P., Holroyde C., Armstead B., Fox K., Wein A. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regiment. J. Clin. Oncol. 16:(1):1998;255-260.
17. Redman B.G., Smith D.C., Flaherty L., Du W., Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J. Clin. Oncol. 16:(5):1998;1844-1848.
18. Sternberg C.N., Calabrò F., Pizzocaro G., Marini L., Schnetzer S., Sella A. Chemotherapy with every 2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 92:(12):2001;2993-2998.
19. Meluch A.A., Greco F.A., Burris H.A. III, O'Rourke T., Ortega G., Steis R.G., Morrissey L.H., Johnson V., Hainsworth J.D. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 19:(12):2001;3018-3024.
20. Parameswaran R., Fisch M.J., Ansari R.H., Fox E.P., Sweeney C.J., Einhorn L.H. A hossier oncology group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 20:(1):2001;200a. Abstract.
21. Guardino A.E., Srinivas S. Gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial malignancies. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(2):2002;150b. Abstract.
22. Fechner G.H., Siener R., Reimann M., Strunk R., Golinski C., Heimbach D., Wiebusch H.W., Langbein S., Ehlert C., Bannowsky A., Heidenreich A., Kühn M., Albers P. Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma. J. Urol. 167:(Suppl. 4):2002;284. Abstract.
23. Kaufmann D.S., Carducci M.A., Kuzel T., Todd M.B., Raghavan D., Oh W.K., Smith M.R., Nicol S.J., Stadler W.W. Gemcitabine (G) and paclitaxel (P) every 2 weeks (GP2w): a completed multi-center phase II trial in locally advanced or metastatic urothelial cancer (UC). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(1):2002;192a. Abstract.
24. Manola J.B., Dreicer R., Wilding G. Gemcitabine and docetaxel in advanced carcinoma of the urothelium: report of a phase II Eastern Cooperative Oncology Group trial. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(1):2002;200a.
25. Bellmunt J., Guillem V., Paz-Ares L., González-Larriba J.L., Charles J., Batiste-Alentorn E., Sáenz A., López-Brea M., Font A., Nogué M., Bastus R., Climent M.A., de la Cruz J.J., Albanell J., Banus J.M., Gallardo E., Diaz-Rubio E., Cortes-Funes H., Baselga J. Phase I-II study of paclitaxel, cisplatin and gemcitabine in advanced transitional cell carcinoma of the urothelium. J. Clin. Oncol. 18:(18):2000;3247-3255.
26. de Wit R., Bellmunt J. Overview of gemcitabine triplets in metastatic bladder cancer. Crit. Rev. Oncol. Hematol. 45:2003;191-197.
27. Hussain M., Vaishampayan U., Du W., Redman B., Smith D.C. Combination of paclitaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. 19:(9):2001;2527-2533.
28. Bajorin D.F., McCaffrey J.A., Dodd P.M., Hilton S., Mazumdar M., Kelly W.K., Herr H., Scher H.I., Icasiano E., Higgins G. Ifosfamide, paclitaxel and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer. 88:(7):2000;1671-1678.
29. Dodd P.M., McCaffrey J.A., Hilton S., Mazumdar M., Herr H., Kelly W.K., Icasiano E., Boyle M.G., Bajorin D.F. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 18:(4):2000;840-846.
30. Misset J.L. Brief communication: use of the multi-targeted antifolate pemetrexed (Alimta) in genitourinary cancer. Semin. Oncol. 29:(1, Suppl. 3):2002;36-39.
31. Hanauske A.R., Chen V., Paoletti P., Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 6:(4):2001;363-373.
32. Calvert H., Bunn P.A. Jr. Future directions in the development of pemetrexed. Semin. Oncol. 29:(2, Suppl. 5):2002;54-61.
33. Paz-Ares L., Tabernero J., Moyano A., Rifa J., Gomez H., Marcuello E., Gonzalez A., Tarazona I., Cortés-Funes H. A phase II study of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma (TCC) of the bladder. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 17:1998;339a. Abstract.
34. Moran R.G. Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin. Oncol. 26:(2, Suppl. 6):1999;24-32.
35. Shih C., Chen V.J., Gossett L.S., et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57:(6):1997;1116-1123.
36. Schultz R.M., Chen V.J., Brewley J.R., et al. Biological activity of the multi-targeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin. Oncol. 26:(2, Suppl. 6):1999;68-73.
37. Calvert H. Folate status and the safety profile of antifolates. Semin. Oncol. 29:(2, Suppl. 5):2002;3-7.
38. Shin D.M., Scagliotti G.V., Kindler H.L., et al. A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:2002;294a. Abstract.
39. Yamaguchi H., Paranawithana S.R., Lee M.W., Huang Z., Bhalla K.N., Wang H.G. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res. 62:(2):2002;466-471.
40. Smaletz O., Kelly W.K., Horse-Grant D., et al. Epothilone B analogue (BMS-247550) with estramustine phosphate (EMP) in patients (pts) with progressive castrate-metastatic prostate cancer (PC). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:2002;184a. Abstract.
41. Fahy J. Modifications in the "upper" velbenamine part of the vinca alkaloids have major implications for tubulin interacting activities. Curr. Pharm. Des. 7:(13):2001;1181-1197.
42. Saijo N. Preclinical and clinical trials of topoisomerase inhibitors. Ann. NY Acad. Sci. 922:2000;92-99.
43. Yoshinari T., Ohkubo M., Fukasawa K., Egashira S., Hara Y., Matsumoto M., Nakai K., Arakawa H., Morishima H., Nishimura S. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. 59:(17):1999;4271-4275.
44. Cavazos C.M., Keir S.T., Yoshinari T., Bigner D.D., Friedman H.S. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl)ethylamino-12,13-dihydro-13-(beta-D- glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. 48:(3):2001;250-254.
45. Wang H.K. Flavopiridol. National Cancer Institute. Curr. Opin. Invest. Drugs. 2:(8):2001;1149-1155.
46. Johnston S.R., Kelland L.R. Farnesyl transferase inhibitors - a novel therapy for breast cancer. Endocr. Relat. Cancer. 8:(3):2001;227-235.
47. Singh S.B., Lingham R.B. Current progress on farnesyl protein transferase inhibitors. Curr. Opin. Drug Discov. Dev. 5:(2):2002;225-244.
48. Winquist E., Moore M.J., Chi K., Ernst S., Hirte H., Iscoe N., Venner P., Huan S., Powers J., Seymour L., Boucher T. NCIC CTG IND 128: a phase II study of a farnesyl transferase inhibitor (SCH-66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 20:(1):2001;197a. Abstract.
49. Renhowe P.A. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy - clinical progress. Curr. Opin. Drug Discov. Dev. 5:(2):2002;214-224.
50. Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 94:(5):2002;1593-1611.
51. de Bono J.S., Rowinsky E.K. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 8:(4):2002;S19-S26.
52. Saltz L., Rubin M., Hochster H., Tchekmeydian N.S., Waksal H., Needle M., LoBuglio A. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 20:(1):2001;3a. Abstract.
53. Herbst R.S., Kim E.S., Harari P.M. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin. Biol. Ther. 1:(4):2001;719-732.
54. Inoue K., Slaton J.W., Perrotte P., et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6:(12):2000;4874-4884.
55. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:(11):2001;783-792.
56. Jimenez R.E., Hussain M., Bianco F.J.J., Vaishampayan U., Tabazcka P., Sakr W.A., Pontes J.E., Wood D.P. Jr., Grignon D.J. HER2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 7:(8):2001;2440-2447.
57. Baselga J., Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12:(Suppl. 1):2001;S35-S41.
58. Chapman A.E., Goldstein L.J. Multiple drug resistance: biologic basis and clinical significance in renal cell carcinoma. Semin. Oncol. 22:(10):1995;17-28.
59. Samuels B.L., Hollis D.R., Rosner G.L., et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin. Cancer Res. 3:1997;1977-1984.
60. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163:2000;408-417.
61. de Mulder P.H., Weissbach L., Jakse G., Osieka R., Blatter J. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother. Pharmacol. 37:1996;491-495.
62. Mertens W.C., Eisenhauer E.A., Moore M., et al. Gemcitabine in advanced renal cell carcinoma: a phase II study of the national cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 4:1993;331-332.
63. Mani S., Vogelzang N.J., Bertucci D., Schilsky R., Ratain M.J. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 92:(6):2001;1567-1576.
64. Tippin D.B., Reeves W., Vogelzang N.J. Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-FU and gemcitabine. J. Urol. 162:(1):1999;155-156.
65. Rini B.I., Vogelzang N.J., Dumas M.C., Wade J.L. III, Taber D.A., Stadler W.M. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J. Clin. Oncol. 18:(12):2000;2419-2426.
66. Ryan C.W., Vogelzang N.J., Stadler W.M. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell cancer. Cancer. 94:(10):2002;2602-2609.
67. George C.M., Vogelzang N.J., Rini B.I., Geoffroy F.J., Kollipara P., Stadler W.M. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion 5-fluorouracil in patients with metastatic renal cell carcinoma. Ann. Oncol. 13:(1):2002;116-120.
68. Desai A., Vogelzang N.J., Rini B.I., Ansari R., Krauss S., Stadler W.M. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 95:2002;1629-1636.
69. Schilsky R.L., Bertucci D., Vogelzang N.J., Kindler H.L., Ratain M.J. A dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J. Clin. Oncol. 20:(2):2002;582-587.
70. George C.M., Huo D., Vogelzang N.J., Rini B.I., Ryan C.W., Desai A.A., Stadler W.M. Pooled analysis of advanced renal cell carcinoma (RCC) patients (pts) treated with gemcitabine (G) and 5-fluorouracil (F). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:2002;191a. Abstract.
71. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17:1999;2530-2540.
72. Rosen L.S. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 9:(Suppl. 2):2002;36-44.
73. Yang J.C., Haworth L., Steinberg S.M., Rosenberg S.A., Novotny W. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(1):2002;5a. Abstract.
74. Lara P.N., Quinn D., Margolin K., Meyers F.J., Longmate J., Frankel P., Turrell C., Valk P., Rao J., Buckley P., Doroshow J.H., Gandara D.R. Angiogenesis inhibition in renal cell carcinoma (RCC): a phase II California Cancer Consortium study of SU 5416+interferon with biologic and imaging correlates. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(1):2002;185a. Abstract.
75. Eisen T. Thalidomide in solid malignancies. J. Clin. Oncol. 20:2002;2607-2609.
76. Fishman M., Seigne J., Antonia S. Novel therapies for renal cell carcinoma. Expert Opin. Investig. Drugs. 10:(6):2001;1033-1044.
77. Motzer R.J., Berg W., Ginsberg M., Russo P., Vuky J., Yu R., Bacik J., Mazumdar M. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J. Clin. Oncol. 20:(1):2002;302-306.
78. Stebbing J., Benson C., Eisen T., Pyle L., Smalley K., Bridle H., Mak I., Sapunar F., Ahern R., Gore M.E. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer. 85:(7):2001;953-958.
79. Amato R.J., Breheny S., Tracy E. Phase I/II study of thalidomide and interleukin-II (IL-2) for patients with metastatic renal cell carcinoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(1):2002;190a. Abstract.
80. Ridenhour K.P., Kubinski D., Stindt D., Hall M.C., Patton S.E., Torti F.M. Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(2):2002;154b. Abstract.
81. Olencki T., Dreicer R., Elson P., Wood L., Bukowski M. Phase I trial of thalidomide and interleukin-2 (IL-2) in patients (pts) with metastatic renal cell carcinoma (RCC). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(2):2002;154b. Abstract.
82. Gershanovich M.M., Gorelov A.I., Hajba N.N. High-dose toremifene (HDT) for the treatment of locally advanced and metastatic renal cell carcinoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(1):2002;190a. Abstract.
83. Gershanovich M.M., Moiseyenko V.M., Vorobjev A.V., Kapyla H., Ellmen J., Anttila M. High-dose toremifene in advanced renal cell carcinoma. Cancer Chemother. Pharmacol. 39:(6):1997;547-551.
84. Bloom H.J., Roe F.J., Matchley B.C. Sex hormones and renal neoplasia: inhibition of tumor of hamster kidney by an estrogen antagonist, an agent of possible therapeutic value in man. Cancer. 20:(12):1967;2118-2124.
85. Childs R., Chernoff A., Contentin N., Bahceci E., Schrump D., Leitman S., Read E.J., Tisdale J., Dunbar C., Linehan W.M., Young N.S., Barrett A.J. Regression of metastatic renal cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343:(11):2000;750-758.
86. Rini B.I., Zimmerman T.M., Stadler W.M., Gajewski T.F., Vogelzang N.J. Allogeneic stem cell transplantation of renal cell cancer after non-myeloablative chemotherapy: feasibility, engraftment and clinical results. J. Clin. Oncol. 20:2002;2017-2024.
87. Hu H.S., Rini B.I., Zimmerman T.M., Gajewski T.F., Stadler W.M., Vogelzang N.J. Allogeneic stem cell transplantation for metastatic renal cell cancer after non-myeloablative chemotherapy: updated results from the University of Chicago. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:2002;180a.
88. Appelbaum F.R., Sandmaier B. Sensitivity of renal cell cancer to non-myeloablative allogeneic hematopoietic cell transplantations: unusual or unusually important? J. Clin. Oncol. 20:(8):2002;1965-1967.
89. Wada T., Qian X.L., Greene M.I. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell. 61:(7):1990;1339-1347.
90. Drucker B.J., Schwartz L., Marion S., Motzer R. Phase II trial of ZD 1839 (Iressa), an EGF receptor inhibitor, in patients with advanced renal cell carcinoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(1):2002;181a.
91. Lynch D.H., Yang X.D. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol. 29:(1, Suppl. 4):2002;47-50.
92. Perera A.D., Kleymenova E.V., Walker C.L. Requirement for the von Hipple Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin. Cancer Res. 6:(4):2000;1518-1523.
93. Atkins M.B., Hidalgo M., Stadler W., Logan T., Dutcher J.P., Hudes G., Park Y., Marshall B., Boni J., Dukart G. A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21:(1):2002;10a. Abstract.